These data support the need for additional preclinical and clinical studies to determine whether increasing endogenous APN levels or using small molecules that can bind to AdipoR1 and AdipoR2 receptor agonists may abrogate inflammatory injury during early lung development that contributes to BPD. This evidence concerns the gene ADIPOR1 and bronchopulmonary dysplasia.